What is the standard chemotherapy cycle plan for an adult with oral cavity squamous‑cell carcinoma, including dosing schedules, alternatives for cisplatin‑ineligible patients, and considerations for renal function and toxicity?

Oral Cancer Chemotherapy Cycle Plan

For oral cavity squamous cell carcinoma requiring chemotherapy, the standard regimen is cisplatin 100 mg/m² given on days 1,22, and 43 concurrent with radiotherapy (70 Gy), with the critical goal of achieving a cumulative dose ≥200 mg/m² to optimize survival outcomes. 11

Standard Cisplatin Dosing Schedule

Concurrent Chemoradiotherapy (Definitive or Adjuvant)

• High-dose cisplatin: 100 mg/m² IV on days 1,22, and 43 during radiotherapy 11
• Alternative: 20 mg/m² daily for 5 days, repeated on day 22 and 43 2
• Cumulative target: ≥200 mg/m² total dose is associated with significantly improved disease-free survival (median DFS 20.8 vs 10.5 months for <200 mg/m²) 3

Administration Protocol

• Pre-hydration: 1-2 liters of fluid infused 8-12 hours before cisplatin 22
• Infusion: Dilute in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline with 37.5g mannitol, infuse over 6-8 hours 22
• Post-hydration: Maintain adequate hydration and urinary output for 24 hours 2
• Timing: Postoperative RT/CRT must start within 6-7 weeks of surgery 11

Cisplatin-Ineligible Patients

Eligibility Criteria for Cisplatin

Patients are considered ineligible if they have:

• Creatinine clearance <60 mL/min 4
• Grade ≥2 hearing loss or tinnitus 4
• Grade ≥2 peripheral neuropathy 4
• ECOG performance status ≥2 4
• Age >70 years with moderate/severe comorbidities (though chronological age alone should not exclude fit elderly patients) 4

Alternative Regimens for Cisplatin-Ineligible Patients

Carboplatin-based options 11:

• Carboplatin + 5-FU concurrent with RT [II, A]
• Carboplatin AUC 1.5 on days 1-5, repeated day 29-33 (comparable outcomes to cisplatin in retrospective analysis, though prospective data show cisplatin superiority) 56

Cetuximab-based option:

• Cetuximab concurrent with RT [II, A] 1

Alternative RT approaches:

• Hyperfractionated or accelerated RT without chemotherapy [II, A] 1

Important Caveat on Carboplatin

While carboplatin appears safer for renal function, cisplatin demonstrates superior locoregional control and overall survival (3-year LRC: 85% vs 62%; 3-year OS: 78% vs 51%) without increased toxicity in head-to-head comparisons 6. Use carboplatin only when cisplatin is truly contraindicated, not merely for convenience.

Recurrent/Metastatic Disease Chemotherapy

First-Line Treatment (Treatment-Naive or >6 Months from Prior Platinum)

PD-L1 positive (CPS ≥1) 11:

• Pembrolizumab monotherapy [I, A; ESMO-MCBS 4] - preferred for less symptomatic disease
• Pembrolizumab + platinum/5-FU [I, A; ESMO-MCBS 4] - when rapid tumor shrinkage needed

PD-L1 negative or contraindication to immunotherapy 11:

• EXTREME regimen: Cisplatin 100 mg/m² or carboplatin AUC 5 + 5-FU 1000 mg/m²/day × 4 days + cetuximab (400 mg/m² loading, then 250 mg/m² weekly), every 3 weeks [I, A; ESMO-MCBS 3]
• TPeX alternative: Cisplatin/docetaxel/cetuximab [II, B] - consider for DPD deficiency patients 1

Second-Line Treatment (Progression Within 6 Months of Platinum)

Immunotherapy-naive 11:

• Nivolumab 240 mg IV every 2 weeks [I, A; ESMO-MCBS 4] - FDA and EMA approved
• Pembrolizumab 200 mg IV every 3 weeks [I, A] - FDA approved for all; EMA approved only if PD-L1 TPS ≥50%

Post-immunotherapy progression 1:

• No standard of care exists
• Options: Taxanes ± cetuximab ± methotrexate [III, C]
• Cetuximab FDA-approved after platinum failure [III, C]

Critical Monitoring and Toxicity Management

Before Each Cycle

• Serum creatinine must be <1.5 mg/100 mL 22
• BUN must be <25 mg/100 mL 22
• Platelets ≥100,000/mm³ 22
• WBC ≥4,000/mm³ 22
• Audiometric testing confirming normal auditory acuity 22

Renal Function Considerations

• Cisplatin is contraindicated with pre-existing renal impairment 2
• Elderly patients are more susceptible to nephrotoxicity 2
• Dose-related cumulative renal insufficiency is the major dose-limiting toxicity 2
• Monitor creatinine clearance closely; borderline patients (CrCl near 60 mL/min) require individualized assessment 4

Ototoxicity Monitoring

• Perform audiometry before initiation, before each dose, and for several years post-therapy 2
• Children have 40-60% prevalence of hearing loss 2
• Risk increases with: age <5 years, concurrent ototoxic drugs (aminoglycosides, vancomycin), renal impairment, prior cranial irradiation 2

Common Pitfalls to Avoid

1. Do not use aluminum-containing needles or IV sets - causes precipitate formation and potency loss 22
2. Do not give cisplatin by rapid IV injection - must be slow infusion over 6-8 hours 22
3. Do not dilute cisplatin in 5% Dextrose alone - must use 1/2 or 1/3 normal saline 22
4. Do not delay postoperative treatment - entire surgery-to-completion timeline should be ≤11 weeks 1

Weekly vs. Triweekly Cisplatin Debate

Recent evidence shows no significant difference in overall survival between weekly cisplatin (30-50 mg/m²) and triweekly high-dose cisplatin (100 mg/m²), though this remains controversial 78. However:

• Triweekly regimen achieves higher cumulative doses more reliably (88.5% vs 62.5% achieving ≥200 mg/m²) 9
• Weekly regimen may have higher overall toxicity in some studies 9
• Triweekly shows better compliance in adjuvant setting 9

The 2020 EHNS-ESMO-ESTRO guidelines explicitly recommend the triweekly 100 mg/m² regimen as standard [II, A] 11, making this the preferred approach unless patient factors necessitate dose modification.